Sodium caseinate nanomicelles as a novel drug delivery system for doxorubicin
-
1
Monash University Malaysia, Malaysia
Background
Breast cancer is the most common cancer amongst women in both the developed and less developed world. It impacts over 1.5 million women worldwide each year. Doxorubicin (DOX) is a widely used drug for breast cancer. However, researchers are still looking for appropriate delivery system that can overcome acquired resistance and toxicity associated with DOX. Casein nanomicelles, the major fraction of milk protein, are emerging as a novel drug delivery system owing to their various structural and functional properties.
Methods
DOX was successfully loaded into sodium caseinate nanomicelles (NaCNs) which were formulated and optimised through magnetic stirring. Zeta size and zeta potential of formulations were measured and then formulations were further characterised through FESEM, TEM, FTIR and XRD. In-vitro drug release study was also assessed by using dialysis membrane.
Results
NaCNs yielded sizes that ranged from 348.8 nm (blank micelles) to 604 nm (drug-loaded micelles) and, negative zeta potential of -22.1 (blank micelles) to -21.9 mV (drug-loaded micelles). DOX showed significant encapsulation efficiency (71.57% ± 4.855) and drug loading (2.01±0.095). Morphological characterisation through FESEM and TEM revealed the spherical morphology of micelles of both unloaded and loaded micelles. XRD data confirmed the amorphous nature of the formulated drug-loaded micelles. FTIR spectra indicated the proper entrapment of the drug and confirmed no chemical interaction between the drug and the micelles. Drug release profile of the loaded micelles revealed that the colloidal drug carrier could release the drug in a slow manner under normal physiological conditions.
Conclusion
The present findings implied the potential of overcoming the limitations associated with DOX by formulating DOX-loaded NaCNs against breast cancer.
Keywords:
breast cancer,
Nanomicelles,
Doxorubicin,
FESEM,
Encapsulation efficiency
Conference:
International Conference on Drug Discovery and Translational Medicine 2018 (ICDDTM '18)
“Seizing Opportunities and Addressing Challenges of Precision Medicine”, Putrajaya, Malaysia, 3 Dec - 5 Feb, 2019.
Presentation Type:
Oral Presentation
Topic:
Cancer
Citation:
Rehan
F,
Gupta
M and
Ahemad
N
(2019). Sodium caseinate nanomicelles as a novel drug delivery system for doxorubicin.
Front. Pharmacol.
Conference Abstract:
International Conference on Drug Discovery and Translational Medicine 2018 (ICDDTM '18)
“Seizing Opportunities and Addressing Challenges of Precision Medicine”.
doi: 10.3389/conf.fphar.2018.63.00004
Copyright:
The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers.
They are made available through the Frontiers publishing platform as a service to conference organizers and presenters.
The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated.
Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed.
For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions.
Received:
30 Sep 2018;
Published Online:
17 Jan 2019.
*
Correspondence:
Ms. Farah Rehan, Monash University Malaysia, Bandar Sunway, Malaysia, farah.rehan@monash.edu
Dr. Manish Gupta, Monash University Malaysia, Bandar Sunway, Malaysia, manugupta1@gmail.com
Dr. Nafees Ahemad, Monash University Malaysia, Bandar Sunway, Malaysia, Nafees.Ahemad@monash.edu